Paper - WANFANG MED ONLINE

You Position: Home > Paper

内镜下逆行胰胆管造影术围手术期用药专家共识意见(2018年,南昌)

( views:52, downloads:323 )

Author:: No author available

Journal Title:: Chinese Journal of Pancreatology

Issue:: 5

DOI:: 10.3760/cma.j.issn.1674-1935.2018.05.002

Key Word:: No keyword available

Abstract：内镜下逆行胰胆管造影术(endoscopic retrograde cholangiopancreatography,ERCP)已广泛应用于胆胰疾病的诊治,但ERCP操作有一定并发症发生率,主要包括术后胰腺炎(post-ERCP pancreatitis,PEP)、出血、感染,穿孔等.围手术期合理应用药物可有效降低ERCP术后并发症,然而目前对ERCP的围手术期合理用药认识存在明显不足,围手术期合理使用预防药物的比例较低[1-2].目前关于ERCP围手术期用药的研究繁多,但结论不一,2015年我国制定了《内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(2015年,上海)》[3],近年来随着对ERCP围手术期用药研究的报道数量不断增加,其中来自中国的临床研究占30％以上,为此中国医师协会内镜医师分会消化内镜专业委员会与中国医师协会胰腺病专业委员会于2018年5月在江西南昌组织召开了“ERCP围手术期用药专家共识意见研讨会”,经与会专家充分讨论后形成了本共识意见,供广大临床医师参考借鉴.

Reference

[1]Min Chen,Lei Wang,Yun Wang,etc.Risk factor analysis of post-ERCP cholangitis: A single-center experience[J].2018,(1).
[2]Nam Hee Kim,Hong Joo Kim,Ki Bae Bang.Prospective comparison of prophylactic anti-biotic use between intravenous moxifloxacin and ceftriaxone for high-risk patients with post-ERCP cholangitis[J].2017,(5).
[3]中华医学会消化内镜分会ERCP学组.ERCP诊治指南（2010版）（三）[J].2010,(5).
[4]ZHANG Zhi-feng,Yang Ning,ZHAO Gang,etc.Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis[J].2010,(18).
[5]中国医师协会胰腺病学专业委员会.中国急性胰腺炎多学科（MDT）诊治共识意见（草案）[J].2015,(4).
[6]中华医学会消化内镜分会ERCP学组.ERCP诊治指南（2010版）（一）[J].2010,(3).
[7]De-Min Li,Jie ZHAO,Qiu Zhao,etc.Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography for Common Bile Duct Stones in Liver Cirrhotic Patients[J].2014,(4).
[8]中华医学会消化内镜分会ERCP学组.ERCP诊治指南（2010版）（二）[J].2010,(4).
[9]中华医学会消化内镜学分会,中国医师协会胰腺病专业委员会.内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见（2015年，上海）[J].2015,(12).
[10]Jeremy J, Schwartz,Ronald J, Lew,Nuzhat A, Ahmad,etc.The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis.[J].2004,59(2).
[11]Gao J,Bai Y,Zou D,etc.Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.[J].2008,8(4).
[12]Shaffer R S, Mok,Murtaza, Arif,David L, Diehl,etc.Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation.[J].2017,5(3).
[13]Choi, Cheol Woong,Park, Su Bum,Kang, Dae Hwan,etc.A Randomized Comparative Study of 24-and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis A Prospective Randomized Comparison Trial[J].2016,45(8).
[14]Jianhua Wan,Yuping Ren,Zhenhua Zhu,etc.How to select patients and timing for rectal indomethacin to prevent post-ERCP pancreatitis: a systematic review and meta-analysis.[J].2017,17.
[15]Víctor Fernando, Andrade-Dávila,Mariana, Chávez-Tostado,Carlos, Dávalos-Cobián,etc.Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.[J].2015,15.
[16]Steven F. Millward.ACR Appropriateness Criteria?on Treatment of Acute Nonvariceal Gastrointestinal Tract Bleeding[J].2008,5(4).
[17]Lin-Lee Wong,Her-Hsin Tsai.Prevention of post-ERCP pancreatitis[J].2014,(1).
[18]J. Sand,I. Nordback.Prospective Randomized Trial of the Effect of Nifedipine on Pancreatic Irritation after Endoscopic Retrograde Cholangiopancreatography[J].1993,54(2).
[19]Panagiotis Katsinelos,Jannis Kountouras,George Paroutoglou,etc.Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis[J].2005,62(1).
[20]Frédéric Prat,Juan Amaris,Béatrice Ducot,etc.Nifedipine for prevention of post-ERCP pancreatitis: A prospective, double-blind randomized study[J].2002,56(2).
[21]Ruth Dunne,Eoghan McCarthy,Eimear Joyce,etc.Post-endoscopic biliary sphincterotomy bleeding: an interventional radiology approach[J].2013,54(10).
[22]Chey W,Gorelick A,Elta G,etc.Botulinum toxin injection after biliary sphincterotomy.[J].2004,36(2).
[23]Koksal, Ali Riza,Boga, Salih,Alkim, Huseyin,etc.Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study[J].2016,61(8).
[24]Li, Lin,Han, Zhen,Yuan, Heming,etc.Nonsteroidal anti-inflammatory drugs reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis[J].2017,24(9).
[25]Logan RF,Veitch P,Fairclough P,etc.Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study.[J].2007,39(9).
[26]Kochar, Bharati,Akshintala, Venkata S.,Afghani, Elham,etc.Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials[J].2015,81(1).
[27]Zhao, Zhen-Hua,Hu, Liang-Hao,Ren, Hong-Bo,etc.Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis[J].2017,86(3).
[28].Endoscopic retrograde cholangiopancreatography-related adverse events. General overview[J].2015,25(1).
[29]Li, Zhao-Shen,Pan, Xue,Zhang, Wen-Jun,etc.Effect of Octreotide Administration in the Prophylaxis of Post-ERCP Pancreatitis and Hyperamylasemia: A Multicenter, Placebo-Controlled, Randomized Clinical Trial.[J].2007,102(1).
[30]Andriulli, Angelo,Loperfido, Silvano,Napolitano, Grazia,etc.Incidence Rates of Post-ERCP Complications: A Systematic Survey of Prospective Studies.[J].2007,102(8).
[31]Gao J,Bai Y,Zou D,etc.Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis.[J].2008,28(5).
[32]Norman Oneil, Machado.Management of duodenal perforation post-endoscopic retrograde cholangiopancreatography. When and whom to operate and what factors determine the outcome? A review article.[J].2012,13(1).
[33]Tae Yoon, Lee,Jung Sik, Choi,Hyoung-Chul, Oh,etc.Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.[J].2015,30.
[34]G, Brandst?tter,S, Schinzel,H, Wurzer.Influence of spasmolytic analgesics on motility of sphincter of Oddi.[J].1996,41(9).
[35]Curran CC,Colton JB.Quality indicators, including complications, of ERCP in a community setting: a prospective study.[J].2009,70(3).
[36]Udayakumar, Navaneethan,Basile, Njei,Xiang, Zhu,etc.Safety of ERCP in patients with liver cirrhosis: a national database study.[J].2017,5(4).
[37]Chen,X.,Wu,T.,Li,S.,etc.Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis[J].2012,24(5).
[38]P.B. Cotton,G. Lehman,J. Vennes,etc.Endoscopic sphincterotomy complications and their management: an attempt at consensus[J].1991,37(3).
[39]Halttunen,J.,Lindstr?m,O.,Kyl?np??,L.,etc.Risk factors for complications of ERCP in primary sclerosing cholangitis[J].2012,44(12).
[40]E Masci,G Toti,A Mariani,etc.Complications of diagnostic and therapeutic ERCP: a prospective multicenter study[J].2001,96(2).
[41]Lo AY,Avgerinos DV,Llaguna OH,etc.Management of endoscopic retrograde cholangiopancreatography: related duodenal perforations.[J].2009,23(4).
[42]Wang, Li-Xia,Zhang, Zhi-Feng,Duan, Zhi-Jun,etc.Aggressive Hydration With Lactated Ringer Solution in Prevention of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis A Meta-analysis of Randomized Controlled Trials[J].2017,51(3).
[43]Bai Y,Gao J,Li ZS,etc.Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: a meta-analysis.[J].2009,38(2).
[44]Katsinelos, Panagiotis,Lazaraki, Georgia,Chatzimavroudis, Grigoris,etc.Impact of nitroglycerin and glucagon administration on selective common bile duct cannulation and prevention of post-ERCP pancreatitis[J].2017,52(1).
[45]Khashab, Mouen A.,Chithadi, Krishnavel V.,Acosta, Ruben D.,etc.Antibiotic prophylaxis for GI endoscopy[J].2015,81(1).
[46]Rai, Uma,Thrimawithana, Thilini R.,Valery, Celine,etc.Therapeutic uses of somatostatin and its analogues: Current view and potential applications[J].2015,152.
[47]Talukdar, Rupjyoti.Complications of ERCP[J].2016,30(5).
[48]Igarashi,M.,Shimosegawa,T.,Yuhara,H.,etc.Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: Protease inhibitors and NSAIDs in a meta-analysis[J].2014,49(3).
[49]Kato, Kunihiro,Shiba, Masatsugu,Kakiya, Yuki,etc.Celecoxib Oral Administration for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis A Randomized Prospective Trial[J].2017,46(7).
[50]Banks,P.A.,Bollen,T.L.,Dervenis,C.,etc.Classification of acute pancreatitis - 2012: Revision of the Atlanta classification and definitions by international consensus[J].2013,62(1).
[51]Wentao Li,Hongji Yang,Nan Peng,etc.Rectal nonsteroidal anti-inflammatory drugs administration is effective for the prevention of post-ERCP pancreatitis: An updated meta-analysis of randomized controlled trials[J].2017,17(5).
[52].Quality assessment of endoscopic retrograde cholangiopancreatography: Results of a running nationwide Austrian benchmarking project after 5 years of implementation[J].2012,24(12).
[53]Navasa M,Cardenas A,Sendino O,etc.Complications after ERCP in liver transplant recipients.[J].2011,74(2).
[54]Gu LG,Wang YM,Lu F,etc.Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by epinephrine sprayed on the papilla.[J].2011,26(7).
[55]Mergener K,Pappas TM,Enns R,etc.ERCP-related perforations: risk factors and management.[J].2002,34(4).
[56]Mina S Hanna,Andrew J Portal,Ashwin D Dha,etc.UK wide survey on the prevention of post-ERCP pancreatitis[J].2014,5(2).
[57]Xu C,Yang X,Bai Y.Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials.[J].2009,41(8).
[58]Shimeno N,Uchida K,Matsushita M,etc.Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis.[J].2009,44(1).
[59]Wu, Dangyan,Wan, Jianhua,Xia, Liang,etc.The Efficiency of Aggressive Hydration With Lactated Ringer Solution for the Prevention of Post-ERCP Pancreatitis A Systematic Review and Meta-analysis[J].2017,51(8).
[60]M Staritz,T Poralla,K Ewe,etc.Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure.[J].1985,26(2).
[61]Yasunaga, Hideo,Isayama, Hiroyuki,Koike, Kazuhiko,etc.Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents[J].2015,47(11).
[62]Paik, Woo Hyun,Yi, Sun Youn,Park, Chang-Hwan,etc.Aggressive intravenous hydration with lactated Ringer's solution for prevention of post-ERCP pancreatitis: a prospective randomized multicenter clinical trial[J].2018,50(4).
[63]Freeman ML,Nelson DB,Sherman S,etc.Complications of endoscopic biliary sphincterotomy.[J].1996,335(13).
[64]J, Devière,O, Le Moine,J L, Van Laethem,etc.Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.[J].2001,120(2).
[65]Wang, Lei,He, Qi Bin,Wang, Jing,etc.Risk factors for post-ERCP pancreatitis and hyperamylasemia: A retrospective single-center study[J].2015,16(8).
[66]A, Lavy,A, Karban,A, Suissa,etc.Natural beta-carotene for the prevention of post-ERCP pancreatitis.[J].2004,29(2).
[67]KUN ZHU,JIAN-PING WANG,JIN-GEN SU..Prophylactic ulinastatin administration for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis.[J].2017,14(4).
[68]Ignasi, Puig,Xavier, Calvet,Mireia, Baylina,etc.How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis.[J].2014,9(3).
[69]Jacobs JL,Mine T,Fukui T,etc.Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis.[J].2010,45(8).
[70]Xie, Qin,Wen S, Lei,Zhang X, Xing,etc.Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis: an updated meta-analysis.[J].1900,21.
[71]Chen QB,Gao ZY,Zhang Y,etc.Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses.[J].2009,29(11).
[72]Kumbhari, Vivek,Sinha, Amitasha,Reddy, Aditi,etc.Algorithm for the management of ERCP-related perforations[J].2016,83(5).
[73]Fonkalsrud, Lisa,Cash, Brooks D.,Early, Dayna S.,etc.The management of antithrombotic agents for patients undergoing GI endoscopy[J].2016,83(1).
[74]Dumonceau,J.-M.,Andriulli,A.,Elmunzer,B.J.,etc.Prophylaxis of post-ERCP pancreatitis: European society of gastrointestinal endoscopy (ESGE) guideline - Updated June 2014[J].2014,46(9).
[75]Wang, Guiliang,Xiao, Gui,Xu, Linfang,etc.Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: A systematic review and meta-analysis[J].2018,18(4).
[76]Inamdar, Sumant,Berzin, Tyler M.,Sejpal, Divyesh V.,etc.Pregnancy Is a Risk Factor for Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in a National Cohort Study[J].2016,14(1).
[77]Knight, Evelyn,Vanbiervliet, Geoffroy,Smith, Lesley-Ann,etc.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines[J].2016,65(3).
[78]Cotton PB,Gallagher J,Garrow DA.Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years.[J].2009,70(1).
[79]Curioni S,Masci E,Mariani A,etc.Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis.[J].2003,35(10).
[80]Mok, Shaffer R. S.,Ho, Henry C.,Shah, Paurush,etc.Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial[J].2017,85(5).
[81]Patai, Arpad,Solymosi, Norbert,Mohacsi, Laszlo,etc.Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials[J].2017,85(6).
[82]Levenick, John M.,Gordon, Stuart R.,Fadden, Linda L.,etc.Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients[J].2016,150(4).
[83]Fontenot BB,Ruddy JM,Morgan KA,etc.Endoscopic retrograde cholangiopancreatography gut perforations: when to wait! When to operate![J].2009,75(6).